Persistent Ocular Hypertension Following Intravitreal Bevacizumab and Ranibizumab Injections
To study ocular hypertension (OHT) following intravitreal injections of bevacizumab and/or ranibizumab in patients with age-related macular degeneration (AMD). Retrospective case series. Patients with AMD who were treated at a tertiary referral center with intravitreal bevacizumab and/or ranibizumab...
Gespeichert in:
| Veröffentlicht in: | Journal of ocular pharmacology and therapeutics 2010-02, Vol.26 (1), p.105-110 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 110 |
|---|---|
| container_issue | 1 |
| container_start_page | 105 |
| container_title | Journal of ocular pharmacology and therapeutics |
| container_volume | 26 |
| creator | ADELMAN, Ron A QI ZHENG MAYER, Hylton R |
| description | To study ocular hypertension (OHT) following intravitreal injections of bevacizumab and/or ranibizumab in patients with age-related macular degeneration (AMD).
Retrospective case series. Patients with AMD who were treated at a tertiary referral center with intravitreal bevacizumab and/or ranibizumab injections from January 1, 2006 to December 31, 2008 were studied. The development of OHT following these injections was investigated.
Four out of 116 patients with AMD (3.45%) developed sustained elevated intraocular pressure (IOP) after multiple intravitreal injections of bevacizumab 1.5 mg/0.06 mL and/or ranibizumab 0.5 mg/0.05 mL. An analysis of 4 cases revealed: None of the patients had a previous diagnosis or family history of glaucoma/OHT. Two patients had both bevacizumab and ranibizumab injections. Two patients developed OHT after recent intravitreal ranibizumab and 2 patients after recent intravitreal bevacizumab injection. Two patients were pseudophakic with a history of YAG capsulotomy. The range of preinjection IOP was 8-15 mmHg (mean, 13 mmHg). The range of postinjection IOP was 28-36 mmHg (mean, 31.75 mmHg). The range of IOP increase was 17-21 mmHg (mean, 18.75 mmHg). Mean number of pan-anti-VEGF injections prior to OHT was 13.3 (range, 3-19). A disrupted posterior capsule might predispose patients to the development of OHT.
Persistent OHT may occur after intravitreal anti-VEGF injection in patients with no previous diagnosis of glaucoma or OHT. OHT may persist across several visits and patients may require IOP-lowering therapy. Sustained elevation in IOP usually occurs after multiple injections. |
| doi_str_mv | 10.1089/jop.2009.0076 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733292094</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733292094</sourcerecordid><originalsourceid>FETCH-LOGICAL-c388t-39f668597023e066c56bece3b88563e926f7ab7e306a0c07080f356ddb9baa113</originalsourceid><addsrcrecordid>eNpFkNFLwzAQh4MoOqePvkpfxKfOS2OT9FGHusFAEX0TyjW7SkaXzqSdzL_eDKc-5XJ89-PuY-yMw4iDLq4W7WqUARQjACX32IDnuUqVEtl-rEFDqqQWR-w4hAUAFyD5ITvKgGulQQ3Y2xP5YENHrkseTd-gTyabFfnYCLZ1yX3bNO2nde_J1HUe17bzhE1yS2s09qtfYpWgmyfP6Gy1-0_dgkwXh8MJO6ixCXS6e4fs9f7uZTxJZ48P0_HNLDVC6y4VRS2lzgsFmSCQ0uSyIkOi0jqXgopM1gorRXF5BAMqXlWLXM7nVVEhci6G7PInd-Xbj55CVy5tMNQ06KjtQ6mEyIoMiutIpj-k8W0Inupy5e0S_abkUG59ltFnufVZbn1G_nyX3FdLmv_RvwIjcLEDMBhsao_O2PDPZTmXMVd8A4NSfvs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733292094</pqid></control><display><type>article</type><title>Persistent Ocular Hypertension Following Intravitreal Bevacizumab and Ranibizumab Injections</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>ADELMAN, Ron A ; QI ZHENG ; MAYER, Hylton R</creator><creatorcontrib>ADELMAN, Ron A ; QI ZHENG ; MAYER, Hylton R</creatorcontrib><description>To study ocular hypertension (OHT) following intravitreal injections of bevacizumab and/or ranibizumab in patients with age-related macular degeneration (AMD).
Retrospective case series. Patients with AMD who were treated at a tertiary referral center with intravitreal bevacizumab and/or ranibizumab injections from January 1, 2006 to December 31, 2008 were studied. The development of OHT following these injections was investigated.
Four out of 116 patients with AMD (3.45%) developed sustained elevated intraocular pressure (IOP) after multiple intravitreal injections of bevacizumab 1.5 mg/0.06 mL and/or ranibizumab 0.5 mg/0.05 mL. An analysis of 4 cases revealed: None of the patients had a previous diagnosis or family history of glaucoma/OHT. Two patients had both bevacizumab and ranibizumab injections. Two patients developed OHT after recent intravitreal ranibizumab and 2 patients after recent intravitreal bevacizumab injection. Two patients were pseudophakic with a history of YAG capsulotomy. The range of preinjection IOP was 8-15 mmHg (mean, 13 mmHg). The range of postinjection IOP was 28-36 mmHg (mean, 31.75 mmHg). The range of IOP increase was 17-21 mmHg (mean, 18.75 mmHg). Mean number of pan-anti-VEGF injections prior to OHT was 13.3 (range, 3-19). A disrupted posterior capsule might predispose patients to the development of OHT.
Persistent OHT may occur after intravitreal anti-VEGF injection in patients with no previous diagnosis of glaucoma or OHT. OHT may persist across several visits and patients may require IOP-lowering therapy. Sustained elevation in IOP usually occurs after multiple injections.</description><identifier>ISSN: 1080-7683</identifier><identifier>EISSN: 1557-7732</identifier><identifier>DOI: 10.1089/jop.2009.0076</identifier><identifier>PMID: 20187807</identifier><language>eng</language><publisher>Larchmont, NY: Liebert</publisher><subject>Aged ; Aged, 80 and over ; Antibodies, Monoclonal - administration & dosage ; Antibodies, Monoclonal - adverse effects ; Antibodies, Monoclonal, Humanized ; Bevacizumab ; Biological and medical sciences ; Drug Administration Schedule ; Drug Therapy, Combination ; Female ; Glaucoma and intraocular pressure ; Humans ; Injections, Intraocular ; Intraocular Pressure - drug effects ; Macular Degeneration - drug therapy ; Male ; Medical sciences ; Ocular Hypertension - chemically induced ; Ocular Hypertension - physiopathology ; Ophthalmology ; Pharmacology. Drug treatments ; Ranibizumab ; Retrospective Studies ; Time Factors ; Vascular Endothelial Growth Factor A - antagonists & inhibitors ; Vitreous Body</subject><ispartof>Journal of ocular pharmacology and therapeutics, 2010-02, Vol.26 (1), p.105-110</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c388t-39f668597023e066c56bece3b88563e926f7ab7e306a0c07080f356ddb9baa113</citedby><cites>FETCH-LOGICAL-c388t-39f668597023e066c56bece3b88563e926f7ab7e306a0c07080f356ddb9baa113</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22516108$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20187807$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>ADELMAN, Ron A</creatorcontrib><creatorcontrib>QI ZHENG</creatorcontrib><creatorcontrib>MAYER, Hylton R</creatorcontrib><title>Persistent Ocular Hypertension Following Intravitreal Bevacizumab and Ranibizumab Injections</title><title>Journal of ocular pharmacology and therapeutics</title><addtitle>J Ocul Pharmacol Ther</addtitle><description>To study ocular hypertension (OHT) following intravitreal injections of bevacizumab and/or ranibizumab in patients with age-related macular degeneration (AMD).
Retrospective case series. Patients with AMD who were treated at a tertiary referral center with intravitreal bevacizumab and/or ranibizumab injections from January 1, 2006 to December 31, 2008 were studied. The development of OHT following these injections was investigated.
Four out of 116 patients with AMD (3.45%) developed sustained elevated intraocular pressure (IOP) after multiple intravitreal injections of bevacizumab 1.5 mg/0.06 mL and/or ranibizumab 0.5 mg/0.05 mL. An analysis of 4 cases revealed: None of the patients had a previous diagnosis or family history of glaucoma/OHT. Two patients had both bevacizumab and ranibizumab injections. Two patients developed OHT after recent intravitreal ranibizumab and 2 patients after recent intravitreal bevacizumab injection. Two patients were pseudophakic with a history of YAG capsulotomy. The range of preinjection IOP was 8-15 mmHg (mean, 13 mmHg). The range of postinjection IOP was 28-36 mmHg (mean, 31.75 mmHg). The range of IOP increase was 17-21 mmHg (mean, 18.75 mmHg). Mean number of pan-anti-VEGF injections prior to OHT was 13.3 (range, 3-19). A disrupted posterior capsule might predispose patients to the development of OHT.
Persistent OHT may occur after intravitreal anti-VEGF injection in patients with no previous diagnosis of glaucoma or OHT. OHT may persist across several visits and patients may require IOP-lowering therapy. Sustained elevation in IOP usually occurs after multiple injections.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antibodies, Monoclonal - administration & dosage</subject><subject>Antibodies, Monoclonal - adverse effects</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Bevacizumab</subject><subject>Biological and medical sciences</subject><subject>Drug Administration Schedule</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Glaucoma and intraocular pressure</subject><subject>Humans</subject><subject>Injections, Intraocular</subject><subject>Intraocular Pressure - drug effects</subject><subject>Macular Degeneration - drug therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Ocular Hypertension - chemically induced</subject><subject>Ocular Hypertension - physiopathology</subject><subject>Ophthalmology</subject><subject>Pharmacology. Drug treatments</subject><subject>Ranibizumab</subject><subject>Retrospective Studies</subject><subject>Time Factors</subject><subject>Vascular Endothelial Growth Factor A - antagonists & inhibitors</subject><subject>Vitreous Body</subject><issn>1080-7683</issn><issn>1557-7732</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkNFLwzAQh4MoOqePvkpfxKfOS2OT9FGHusFAEX0TyjW7SkaXzqSdzL_eDKc-5XJ89-PuY-yMw4iDLq4W7WqUARQjACX32IDnuUqVEtl-rEFDqqQWR-w4hAUAFyD5ITvKgGulQQ3Y2xP5YENHrkseTd-gTyabFfnYCLZ1yX3bNO2nde_J1HUe17bzhE1yS2s09qtfYpWgmyfP6Gy1-0_dgkwXh8MJO6ixCXS6e4fs9f7uZTxJZ48P0_HNLDVC6y4VRS2lzgsFmSCQ0uSyIkOi0jqXgopM1gorRXF5BAMqXlWLXM7nVVEhci6G7PInd-Xbj55CVy5tMNQ06KjtQ6mEyIoMiutIpj-k8W0Inupy5e0S_abkUG59ltFnufVZbn1G_nyX3FdLmv_RvwIjcLEDMBhsao_O2PDPZTmXMVd8A4NSfvs</recordid><startdate>20100201</startdate><enddate>20100201</enddate><creator>ADELMAN, Ron A</creator><creator>QI ZHENG</creator><creator>MAYER, Hylton R</creator><general>Liebert</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20100201</creationdate><title>Persistent Ocular Hypertension Following Intravitreal Bevacizumab and Ranibizumab Injections</title><author>ADELMAN, Ron A ; QI ZHENG ; MAYER, Hylton R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c388t-39f668597023e066c56bece3b88563e926f7ab7e306a0c07080f356ddb9baa113</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antibodies, Monoclonal - administration & dosage</topic><topic>Antibodies, Monoclonal - adverse effects</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Bevacizumab</topic><topic>Biological and medical sciences</topic><topic>Drug Administration Schedule</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Glaucoma and intraocular pressure</topic><topic>Humans</topic><topic>Injections, Intraocular</topic><topic>Intraocular Pressure - drug effects</topic><topic>Macular Degeneration - drug therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Ocular Hypertension - chemically induced</topic><topic>Ocular Hypertension - physiopathology</topic><topic>Ophthalmology</topic><topic>Pharmacology. Drug treatments</topic><topic>Ranibizumab</topic><topic>Retrospective Studies</topic><topic>Time Factors</topic><topic>Vascular Endothelial Growth Factor A - antagonists & inhibitors</topic><topic>Vitreous Body</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>ADELMAN, Ron A</creatorcontrib><creatorcontrib>QI ZHENG</creatorcontrib><creatorcontrib>MAYER, Hylton R</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of ocular pharmacology and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>ADELMAN, Ron A</au><au>QI ZHENG</au><au>MAYER, Hylton R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Persistent Ocular Hypertension Following Intravitreal Bevacizumab and Ranibizumab Injections</atitle><jtitle>Journal of ocular pharmacology and therapeutics</jtitle><addtitle>J Ocul Pharmacol Ther</addtitle><date>2010-02-01</date><risdate>2010</risdate><volume>26</volume><issue>1</issue><spage>105</spage><epage>110</epage><pages>105-110</pages><issn>1080-7683</issn><eissn>1557-7732</eissn><abstract>To study ocular hypertension (OHT) following intravitreal injections of bevacizumab and/or ranibizumab in patients with age-related macular degeneration (AMD).
Retrospective case series. Patients with AMD who were treated at a tertiary referral center with intravitreal bevacizumab and/or ranibizumab injections from January 1, 2006 to December 31, 2008 were studied. The development of OHT following these injections was investigated.
Four out of 116 patients with AMD (3.45%) developed sustained elevated intraocular pressure (IOP) after multiple intravitreal injections of bevacizumab 1.5 mg/0.06 mL and/or ranibizumab 0.5 mg/0.05 mL. An analysis of 4 cases revealed: None of the patients had a previous diagnosis or family history of glaucoma/OHT. Two patients had both bevacizumab and ranibizumab injections. Two patients developed OHT after recent intravitreal ranibizumab and 2 patients after recent intravitreal bevacizumab injection. Two patients were pseudophakic with a history of YAG capsulotomy. The range of preinjection IOP was 8-15 mmHg (mean, 13 mmHg). The range of postinjection IOP was 28-36 mmHg (mean, 31.75 mmHg). The range of IOP increase was 17-21 mmHg (mean, 18.75 mmHg). Mean number of pan-anti-VEGF injections prior to OHT was 13.3 (range, 3-19). A disrupted posterior capsule might predispose patients to the development of OHT.
Persistent OHT may occur after intravitreal anti-VEGF injection in patients with no previous diagnosis of glaucoma or OHT. OHT may persist across several visits and patients may require IOP-lowering therapy. Sustained elevation in IOP usually occurs after multiple injections.</abstract><cop>Larchmont, NY</cop><pub>Liebert</pub><pmid>20187807</pmid><doi>10.1089/jop.2009.0076</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1080-7683 |
| ispartof | Journal of ocular pharmacology and therapeutics, 2010-02, Vol.26 (1), p.105-110 |
| issn | 1080-7683 1557-7732 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733292094 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Aged Aged, 80 and over Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal, Humanized Bevacizumab Biological and medical sciences Drug Administration Schedule Drug Therapy, Combination Female Glaucoma and intraocular pressure Humans Injections, Intraocular Intraocular Pressure - drug effects Macular Degeneration - drug therapy Male Medical sciences Ocular Hypertension - chemically induced Ocular Hypertension - physiopathology Ophthalmology Pharmacology. Drug treatments Ranibizumab Retrospective Studies Time Factors Vascular Endothelial Growth Factor A - antagonists & inhibitors Vitreous Body |
| title | Persistent Ocular Hypertension Following Intravitreal Bevacizumab and Ranibizumab Injections |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T12%3A05%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Persistent%20Ocular%20Hypertension%20Following%20Intravitreal%20Bevacizumab%20and%20Ranibizumab%20Injections&rft.jtitle=Journal%20of%20ocular%20pharmacology%20and%20therapeutics&rft.au=ADELMAN,%20Ron%20A&rft.date=2010-02-01&rft.volume=26&rft.issue=1&rft.spage=105&rft.epage=110&rft.pages=105-110&rft.issn=1080-7683&rft.eissn=1557-7732&rft_id=info:doi/10.1089/jop.2009.0076&rft_dat=%3Cproquest_cross%3E733292094%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733292094&rft_id=info:pmid/20187807&rfr_iscdi=true |